All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

184

Reset

184 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • DNA VaccinePhase 22 trials

    NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)

  • DS-8201Phase 22 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Breast Cancer, Advanced Solid Tumor

  • endoxifenPhase 22 trials

    Atossa Therapeutics, Inc. · Precocious Puberty, Gonadotropin-dependent, Breast Neoplasms, Invasive Breast Cancer

  • FWD1802Phase 22 trials

    Forward Pharmaceuticals Co., Ltd. · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV

  • GI-102Phase 22 trials

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)

  • HRS-1358Phase 22 trials

    Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors

  • HRS-6208Phase 22 trials

    Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer of Adults, Prostate Cancer

  • HRS-9813Phase 22 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors, IPF and PPF

  • LS301-ITPhase 22 trials

    Integro Theranostics · Non Small Cell Lung Cancer (NSCLC), Breast Cancer, DCIS

  • MRT-2359Phase 22 trials

    Monte Rosa Therapeutics, Inc · Prostate Cancer, NSCLC, SCLC

  • PF-07104091ovarian, SCLCPhase 22 trials

    Pfizer · Breast Cancer, Solid Tumors, Small Cell Lung Cancer

  • QLC1401Phase 22 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced Breast Cancer, Advanced ER+/HER2- Breast Cancer

  • SapanisertibFTH-003, MLN0128Phase 22 trials

    Faeth Therapeutics · Endometrial Cancer, HR+ HER2- Breast Cancer

  • SelicrelumabPhase 22 trials

    Roche (Genentech) · Metastatic Breast Cancer, Pancreatic Adenocarcinoma

  • SerabelisibFTH-001, MLN1117Phase 22 trials

    Faeth Therapeutics · Endometrial Cancer, HR+ HER2- Breast Cancer

  • SKB103Phase 22 trials

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Advanced Solid Tumors, Breast Cancer

  • SSGJ-612HER2-targeted antibodyPhase 22 trials

    Shenyang Sunshine Pharmaceutical Co., LTD. · Locally Advanced (Unresectable) or Metastatic Solid Tumors, Metastatic Breast Cancer

  • STAR0602InvikafuspPhase 22 trials

    Marengo Therapeutics, Inc. · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumors

  • SYH2051Phase 22 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Breast Cancer

  • TYK-00540Phase 22 trials

    TYK Medicines, Inc · mCRPC, HR-positive, HER2-negative Advanced Breast Cancer

  • MediLink Therapeutics (Suzhou) Co., Ltd. · NSCLC, Breast Cancer, HNSCC

  • ACE-86225106Phase 21 trial

    Acerand Therapeutics (Shanghai) Limited · Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation

  • AMXI-5001Phase 21 trial

    AtlasMedx, Incorporated · Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer

  • ARX788Phase 21 trial

    Ambrx, Inc. · HER2 Positive Metastatic Breast Cancer

  • ATX-295Phase 21 trial

    Accent Therapeutics · Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer

  • AVZO-023Phase 21 trial

    Avenzo Therapeutics, Inc. · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer

  • AZD6750Phase 21 trial

    AstraZeneca · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)

  • AZD8205Phase 21 trial

    AstraZeneca · Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer

  • AZD8421Phase 21 trial

    AstraZeneca · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

  • BB-1701Phase 21 trial

    Eisai · Breast Cancer

  • BCD-236Phase 21 trial

    Biocad · Triple Negative Breast Cancer

  • BL0175Phase 21 trial

    Shanghai Best-Link Bioscience, LLC · Breast Cancer (Locally Advanced or Metastatic)

  • CBX-12Phase 21 trial

    Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma

  • CFI-402257Phase 21 trial

    Treadwell Therapeutics, Inc · Advanced Solid Tumor, Breast Cancer

  • CRG-150Phase 21 trial

    CoRegen, Inc. · HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer

  • CYT-0851Phase 21 trial

    Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma

  • ECI830Phase 21 trial

    Novartis · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer

  • EfineptakinNT-I7, rhIL-7-hyFcPhase 21 trial

    NeoImmuneTech · Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer

  • ENV-501Phase 21 trial

    Hummingbird Bioscience · Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer

  • EP0062Phase 21 trial

    Ellipses Pharma · Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

  • ETX-19477Phase 21 trial

    858 Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer

  • ETX-636Phase 21 trial

    Ensem Therapeutics · Advanced Solid Tumors, Advanced Breast Cancer

  • EvexomostatSDX-7320Phase 21 trial

    SynDevRx, Inc. · HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer

  • FluvustatPhase 21 trial

    Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer

  • GB268Phase 21 trial

    Eddingpharm (Zhuhai) Co., Ltd. · Breast Cancer (Locally Advanced or Metastatic)

  • GDC-4198RGT-419B, RO7840734Phase 21 trial

    Roche (Genentech) · Breast Cancer

  • GM103Phase 21 trial

    GeneMedicine Co., Ltd. · Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer

  • GTAEXS617REC-617Phase 21 trial

    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)

  • GVV858Phase 21 trial

    Novartis · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer

  • HP568Phase 21 trial

    Hinova Pharmaceuticals Inc. · Breast Cancer

NewerPage 3 of 4Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.